An important part of the work up for patients with hypertrophic cardiomyopathy is an assessment of the risk of dangerous heart rhythms. Fortunately, for those patients at risk, there is now the option of protection in the form of an implantable cardioverter defibrillator (ICD).
An ICD is the most effective means of managing the risk of sudden cardiac arrest. This device is recommended for patients with hypertrophic cardiomyopathy with:
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.